Androgen receptor (AR) antagonism triggers acute succinate-mediated adaptive responses to reactivate AR signaling

EMBO Mol Med. 2021 May 7;13(5):e13427. doi: 10.15252/emmm.202013427. Epub 2021 Mar 11.

Abstract

Treatment-induced adaptive pathways converge to support androgen receptor (AR) reactivation and emergence of castration-resistant prostate cancer (PCa) after AR pathway inhibition (ARPI). We set out to explore poorly defined acute adaptive responses that orchestrate shifts in energy metabolism after ARPI and identified rapid changes in succinate dehydrogenase (SDH), a TCA cycle enzyme with well-known tumor suppressor activity. We show that AR directly regulates transcription of its catalytic subunits (SDHA, SDHB) via androgen response elements (AREs). ARPI acutely suppresses SDH activity, leading to accumulation of the oncometabolite, succinate. Succinate triggers calcium ions release from intracellular stores, which in turn phospho-activates the AR-cochaperone, Hsp27 via p-CaMKK2/p-AMPK/p-p38 axis to enhance AR protein stabilization and activity. Activation of this pathway was seen in tissue microarray analysis on prostatectomy tissues and patient-derived xenografts. This adaptive response is blocked by co-targeting AR with Hsp27 under both in vitro and in vivo studies, sensitizing PCa cells to ARPI treatments.

Keywords: Androgen receptor; Hsp27; prostate cancer; succinate; succinate dehydrogenase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androgen Receptor Antagonists* / pharmacology
  • Cell Line, Tumor
  • Humans
  • Male
  • Prostatic Neoplasms*
  • Receptors, Androgen / genetics
  • Succinic Acid

Substances

  • Androgen Receptor Antagonists
  • Receptors, Androgen
  • Succinic Acid